Calcium channel blockers and cancer: A risk analysis using the UK Clinical Practice Research Datalink (CPRD)

BMJ Open

Volumn 6, Issue 1, 2016, Pages

  Grimaldi Bensouda, Lamiae ^a,b   Klungel, Olaf ^c   Kurz, Xavier ^d   De Groot, Mark C H ^c   Afonso, Ana S Maciel ^c   De Bruin, Marie L ^c   Reynolds, Robert ^e,f   Rossignol, Michel ^g  

^a LA SER   (France)

^b University of Paris Cité   (France)

^c UTRECHT UNIVERSITY   (Netherlands)

^d EUROPEAN MEDICINES AGENCY   (United Kingdom)

^e Pfizer Epidemiology   (United States)

^f TULANE UNIVERSITY   (United States)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEPRIDIL; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; FENDILINE; GALLOPAMIL; LIDOFLAZINE; PERHEXILINE; VERAPAMIL; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CLINICAL PRACTICE; COHORT ANALYSIS; COLON CANCER; DRUG EXPOSURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRESCRIPTION; PROSTATE CANCER; RISK ASSESSMENT; UNITED KINGDOM; ADOLESCENT; INCIDENCE; MIDDLE AGED; NEOPLASMS; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; UNITED KINGDOM; YOUNG ADULT;

EID: 84960455824     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009147     Document Type: Article

References (35)

1. Li CI, Daling JR, Tang MT, et al. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med 2013;173:1629-37.
2. McManus RJ, Caulfield M, Williams B. National Institute for Health and Clinical Excellence. NICE hypertension guideline 2011: evidence based evolution. BMJ 2012;344:e181.
3. Daling JR. Calcium channel blockers and cancer: is an association biologically plausible? Am J Hypertens 1996;9:713-14.
4. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996;348:493-7.
5. Pahor M, Guralnik JM, Salive ME, et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996;9:695-9.
6. Fitzpatrick AL, Daling JR, Furberg CD, et al. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997;80:1438-47.
7. Largent JA, Bernstein L, Horn-Ross PL, et al. Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study cohort. Cancer Causes Control 2010;21:1615-24.
8. Li CI, Malone KE, Weiss NS, et al. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 2003;98:1504-13.
9. Davis S, Mirick DK. Medication use and the risk of breast cancer. Eur J Epidemiol 2007;22:319-25.
10. Fryzek JP, Poulsen AH, Lipworth L, et al. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 2006;97:231-6.
11. Jick H, Jick S, Derby LE, et al. Calcium-channel blockers and risk of cancer. Lancet 1997;349:525-8.
12. Meier CR, Derby LE, Jick SS, et al. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000;160:349-53.
13. Michels KB, Rosner BA, Walker AM, et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the nurses' health study. Cancer 1998;83:2003-7.
14. Perron L, Bairati I, Harel F, et al. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 2004;15:535-41.
15. Vezina RM, Lesko SM, Rosenberg L, et al. Calcium channel blocker use and the risk of prostate cancer. Am J Hypertens 1998;11:1420-5.
16. Hall GC, Sauer B, Bourke A, et al. Guidelines for good database selection and use in pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2012;21:1-10.
17. Abbing-Karahagopian V, Kurz X, de Vries F, et al. Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project. Curr Clin Pharmacol 2014;9:130-8.
18. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14.
19. Nielen MM, Ursum J, Schellevis FG, et al. The validity of the diagnosis of inflammatory arthritis in a large population-based primary care database. BMC Fam Pract 2013;14:79.
20. Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ 2009;338:b81.
21. Shah AD, Martinez C. An algorithm to derive a numerical daily dose from unstructured text dosage instructions. Pharmacoepidemiol Drug Saf 2006;15:161-6.
22. Van Staa TP, Abenhaim L, Cooper C, et al. The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 2000;9:359-6.
23. Lei J, Sockolow P, Guan P, et al. A comparison of electronic health records at two major Peking University Hospitals in China to United States meaningful use objectives. BMC Med Inform Decis Mak 2013;13:96.
24. Beiderbeck-Noll AB, Sturkenboom MC, van der Linden PD, et al. Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study. Eur J Cancer 2003;39:98-105.
25. Pahor M, Furberg CD. Is the use of some calcium antagonists linked to cancer? Evidence from recent observational studies. Drugs Aging 1998;13:99-108.
26. Jick H. Calcium-channel blockers and risk of cancer. Lancet 1997;349:1699-700.
27. Rosenberg L, Rao RS, Palmer JR, et al. Calcium channel blockers and the risk of cancer. JAMA 1998;279:1000-4.
28. Stahl M, Bulpitt CJ, Palmer AJ, et al. Calcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients: a report from the Department of Health Hypertension Care Computing Project (DHCCP). J Hum Hypertens 2000;14:299-304.
29. Boudreau DM, Koehler E, Rulyak SJ, et al. Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 2008;17:3076-80.
30. Bergman GJ, Khan S, Danielsson B, et al. Breast cancer risk and use of calcium channel blockers using Swedish population registries. JAMA Intern Med 2014;174:1700-1.
31. Olsen JH, Sorensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension 1997;29:1091-4.
32. Sørensen HT, Olsen JH, Mellemkjaer L, et al. Cancer risk and mortality in users of calcium channel blockers. A cohort study. Cancer 2000;89:165-70.
33. Cohen HJ, Pieper CF, Hanlon JT, et al. Calcium channel blockers and cancer. Am J Med 2000;108:210-15.
34. González-Pérez A, Ronquist G, Garcia Rodriguez LA. Breast cancer incidence and use of antihypertensive medication in women. Pharmacoepidemiol Drug Saf 2004;13:581-5.
35. Trenkwalder P, Hendricks P, Hense HW. Treatment with calcium antagonists does not increase the risk of fatal or non-fatal cancer in an elderly mid-European population: results from STEPHY II. Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly. J Hypertens 1998;16:1113-16.